Valeo Financial Advisors LLC Reduces Stock Position in Danaher Co. (NYSE:DHR)

Valeo Financial Advisors LLC lowered its stake in Danaher Co. (NYSE:DHR) by 3.0% during the 4th quarter, according to its most recent disclosure with the Securities and Exchange Commission. The fund owned 13,528 shares of the conglomerate’s stock after selling 417 shares during the quarter. Valeo Financial Advisors LLC’s holdings in Danaher were worth $3,105,000 at the end of the most recent quarter.

Several other institutional investors and hedge funds also recently added to or reduced their stakes in DHR. Heck Capital Advisors LLC purchased a new stake in Danaher in the fourth quarter worth approximately $27,000. Decker Retirement Planning Inc. bought a new stake in shares of Danaher during the 4th quarter valued at $31,000. Golden State Wealth Management LLC bought a new stake in shares of Danaher during the 4th quarter valued at $31,000. Strategic Financial Concepts LLC bought a new stake in shares of Danaher during the 4th quarter valued at $31,000. Finally, Pineridge Advisors LLC grew its position in shares of Danaher by 63.3% during the 4th quarter. Pineridge Advisors LLC now owns 147 shares of the conglomerate’s stock valued at $34,000 after acquiring an additional 57 shares during the period. Hedge funds and other institutional investors own 79.05% of the company’s stock.

Insider Transactions at Danaher

In other news, SVP Brian W. Ellis sold 5,700 shares of the business’s stock in a transaction dated Thursday, January 30th. The shares were sold at an average price of $224.13, for a total value of $1,277,541.00. Following the sale, the senior vice president now directly owns 20,230 shares in the company, valued at $4,534,149.90. The trade was a 21.98 % decrease in their position. The transaction was disclosed in a filing with the SEC, which is available at the SEC website. Insiders own 11.10% of the company’s stock.

Danaher Stock Up 1.5 %

Shares of DHR stock opened at $206.66 on Friday. The stock has a market cap of $149.26 billion, a P/E ratio of 39.14, a PEG ratio of 2.68 and a beta of 0.83. Danaher Co. has a 52 week low of $196.80 and a 52 week high of $281.70. The company has a quick ratio of 1.05, a current ratio of 1.40 and a debt-to-equity ratio of 0.31. The company’s fifty day simple moving average is $230.00 and its two-hundred day simple moving average is $249.96.

Danaher (NYSE:DHR) last announced its quarterly earnings results on Wednesday, January 29th. The conglomerate reported $2.14 EPS for the quarter, hitting the consensus estimate of $2.14. Danaher had a net margin of 16.33% and a return on equity of 10.82%. During the same period in the previous year, the company posted $2.09 EPS. Analysts predict that Danaher Co. will post 7.67 EPS for the current fiscal year.

Danaher Announces Dividend

The firm also recently announced a quarterly dividend, which was paid on Friday, January 31st. Stockholders of record on Friday, December 27th were issued a $0.27 dividend. The ex-dividend date of this dividend was Friday, December 27th. This represents a $1.08 dividend on an annualized basis and a dividend yield of 0.52%. Danaher’s dividend payout ratio (DPR) is presently 20.45%.

Analyst Ratings Changes

DHR has been the subject of a number of recent research reports. Wells Fargo & Company cut their price objective on shares of Danaher from $280.00 to $240.00 and set an “equal weight” rating for the company in a research report on Thursday, January 30th. StockNews.com downgraded shares of Danaher from a “buy” rating to a “hold” rating in a research report on Saturday, December 14th. Stifel Nicolaus boosted their price objective on shares of Danaher from $250.00 to $265.00 and gave the company a “hold” rating in a research report on Wednesday, October 23rd. JPMorgan Chase & Co. cut their price objective on shares of Danaher from $310.00 to $300.00 and set an “overweight” rating for the company in a research report on Tuesday, January 28th. Finally, Robert W. Baird cut their price objective on shares of Danaher from $277.00 to $268.00 and set an “overweight” rating for the company in a research report on Tuesday, January 28th. Seven equities research analysts have rated the stock with a hold rating and fifteen have assigned a buy rating to the company’s stock. According to MarketBeat.com, Danaher has an average rating of “Moderate Buy” and a consensus target price of $278.00.

Danaher Profile

Danaher Corporation designs, manufactures, and markets professional, medical, industrial, and commercial products and services worldwide. The Biotechnology segments offers bioprocess technologies, consumables, and services that advance, accelerate, and integrate the development and manufacture of therapeutics; cell line and cell culture media development services; cell culture media, process liquids and buffers for manufacturing, chromatography resins, filtration technologies, aseptic fill finish; single-use hardware and consumables and services, such as the design and installation of full manufacturing suites; lab filtration, separation, and purification; lab-scale protein purification and analytical tools; reagents, membranes, and services; and healthcare filtration solutions.